Details of the Drug Pharmacogenomic Perturbation Atlas

Aspirin Drug Info

ACETYLSALICYLIC ACID; 50-78-2; 2-Acetoxybenzoic acid; o-Acetoxybenzoic acid; O-Acetylsalicylic acid; Polopiryna; Acylpyrin; Ecotrin; Easprin; Acetylsalicylate; Acetophen; Acenterine; Acetosal; Colfarit; Salicylic acid acetate; o-Carboxyphenyl acetate; Enterosarein; Aspergum; Salcetogen; Pharmacin; Acetosalin; Premaspin; Micristin; Benaspir; Aspirdrops; Acetonyl; Aceticyl; Temperal; Acetylin; Empirin; Ecolen; Rhodine; Endydol; Saletin; Rheumintabletten; Solprin acid; Acidum acetylsalicylicum; Globentyl; Pravigard

Therapeutic Class

Analgesics

Cross-matching ID

PubChem CID

2244

ChEBI ID

CHEMBL25

CAS Number

CAS 50-78-2

TTD Drug ID

D0GY5Z

VARIDT Drug ID

DR00203

INTEDE Drug ID

DR1749

ACDINA Drug ID

D00046

General Information of Drug (ID: DM672AH)

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)

Term Name	NES	FDR q-val	Tag %	Leading Edge Genes
ECM-receptor interaction	1.84	2.97e-2	80/88 (90.91%)	LAMB1;TNC;THBS2;...
Pyrimidine metabolism	1.80	3.86e-2	40/56 (71.43%)	CANT1;DCK;CTPS1;...
DNA replication	1.74	4.75e-2	34/36 (94.44%)	PCNA;POLE2;FEN1;...
Epithelial cell signaling in Helicobacter pylori infect...	-1.66	2.91e-2	62/70 (88.57%)	CXCR2;IKBKG;ATP6V0D1;...
Ferroptosis	-1.69	2.11e-2	36/41 (87.8%)	ATG5;GCLM;ATG7;...
Pathways of neurodegeneration	-1.70	1.95e-2	354/475 (74.53%)	DAXX;FZD4;VDAC1;...
D-Glutamine and D-glutamate metabolism	-1.70	2.02e-2	5/5 (100%)	GLUD2;GLUD1
Pathogenic Escherichia coli infection	-1.71	2.04e-2	152/197 (77.16%)	SEC24A;NAIP;PAK2;...
Salmonella infection	-1.72	2.02e-2	198/249 (79.52%)	DYNC2H1;DYNC1I2;TNF;...
Amyotrophic lateral sclerosis	-1.73	1.76e-2	267/364 (73.35%)	COX8A;NDUFA6;DNAI2;...
Non-alcoholic fatty liver disease	-1.73	1.84e-2	126/155 (81.29%)	AKT1;IL1A;NDUFA10;...
Synaptic vesicle cycle	-1.75	1.67e-2	63/78 (80.77%)	UNC13B;ATP6V0D1;ATP6V0E1;...
Legionellosis	-1.75	1.49e-2	51/57 (89.47%)	ARF1;CXCL2;HSPA1L;...
Metabolism of xenobiotics by cytochrome P450	-1.76	1.57e-2	49/77 (63.64%)	GSTK1;CYP1B1;CYP2D6;...
Neutrophil extracellular trap formation	-1.77	1.36e-2	101/189 (53.44%)	HMGB1;VDAC1;RAC2;...
Natural killer cell mediated cytotoxicity	-1.77	1.44e-2	99/131 (75.57%)	KIR2DL3;PAK1;NCR3;...
Inflammatory bowel disease	-1.78	1.28e-2	58/65 (89.23%)	STAT4;RORA;IL1A;...
Prion disease	-1.79	1.28e-2	209/273 (76.56%)	NDUFB8;HSPA1L;COX8A;...
Collecting duct acid secretion	-1.82	9.08e-3	22/27 (81.48%)	ATP6V0D1;ATP6V0E1;ATP6V1A;...
Vibrio cholerae infection	-1.86	6.81e-3	44/50 (88%)	ARF1;ATP6V0D1;ATP6V0E1;...
Alanine, aspartate and glutamate metabolism	-1.87	7.34e-3	27/37 (72.97%)	GAD1;GAD2;GFPT1;...
Huntington disease	-1.88	7.95e-3	233/306 (76.14%)	COX7A1;NDUFA8;COX7C;...
Proteasome	-1.88	6.19e-3	44/46 (95.65%)	PSMC3;ADRM1;PSMA4;...
Necroptosis	-1.91	4.09e-3	113/159 (71.07%)	PPIA;MAPK9;IFNA1;...
Viral myocarditis	-1.95	1.51e-3	53/60 (88.33%)	PRF1;HLA-E;ABL1;...
Parkinson disease	-2.01	1.70e-3	176/249 (70.68%)	NDUFA10;PSMC3;ADRM1;...
Rheumatoid arthritis	-2.03	0.00e+0	78/93 (83.87%)	ATP6V0D1;ATP6V0E1;CXCL2;...
Autoimmune thyroid disease	-2.03	0.00e+0	46/53 (86.79%)	GZMB;PRF1;HLA-E;...
Arginine biosynthesis	-2.10	0.00e+0	17/22 (77.27%)	ARG1;OTC;GOT1;...
Oxidative phosphorylation	-2.21	0.00e+0	93/133 (69.92%)	NDUFS1;COX4I1;COX7A1;...
Allograft rejection	-2.26	0.00e+0	32/38 (84.21%)	IFNG;GZMB;PRF1;...
Graft-versus-host disease	-2.27	0.00e+0	32/42 (76.19%)	IFNG;GZMB;PRF1;...
Type I diabetes mellitus	-2.42	0.00e+0	38/43 (88.37%)	GAD1;IFNG;GZMB;...

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast

Breast adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
MCF7	CVCL_0031	Homo sapiens	0.01uM - 10uM	6H, 24H

Breast epithelium

Normal

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
MCF-10A	CVCL_0598	Homo sapiens	12uM - 100uM	48H

Cervix

Cervical adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HeLa	CVCL_0030	Homo sapiens	0.01uM - 10uM	3H, 24H

Colon

Colorectal adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HT-29	CVCL_0320	Homo sapiens	0.01uM - 10uM	6H, 24H

Kidney

Normal (Immortalized)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HA1E	CVCL_0284	Homo sapiens	0.01uM - 10uM	6H, 24H

Liver

Hepatoblastoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
Hep G2	CVCL_0027	Homo sapiens	0.08uM - 100uM	3H, 24H, 48H

Hepatocellular carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HuH-7	CVCL_0336	Homo sapiens	20uM	72H

Lung

Lung adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A549	CVCL_0023	Homo sapiens	0.01uM - 20uM	6H, 24H

Non-small cell lung carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HCC515	CVCL_5134	Homo sapiens	10uM	6H

Pancreas

Pancreatic carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
YAPC	CVCL_1791	Homo sapiens	0.01uM - 10uM	24H

Prostate

Prostate carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point
PC-3	CVCL_0035	Homo sapiens	0.01uM - 10uM	6H, 24H

VCaP	CVCL_2235	Homo sapiens	10uM	6H, 24H

Skin

Melanoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A-375	CVCL_0132	Homo sapiens	0.01uM - 10uM	6H, 24H